Research Article

Prevalence and Risk Factors Associated with Organ Complications in Patients with COVID 19 Admitted to the Intensive Care Unit: A Cohort Study

Abstract

Background: Exploring risk factors for development of COVID-19 in vital organs of the body is necessary to improve patient survival and reduce disability and morbidity due to disease progression. By identifying these underlying risk factors and controlling them, it is possible to prevent extra-pulmonary involvement and even alleviate pulmonary involvement in patients, resulting in a significant reduction in mortality and morbidity rates. This study aimed to identify the underlying risk factors associated with pulmonary and extrapulmonary organ complications of COVID-19.
Methods: This study was a cross-sectional descriptive-analytical study. Patients with a definitive diagnosis of COVID-19 who were admitted to the intensive care unit of Imam Khomeini Hospital in Tehran due to respiratory distress and poor clinical condition were included in the study population and were clinically followed up on. Patients' information was collected by reviewing patients' records and the hospital information system.
Results: A total of 123 patients were included in the study (63.4% were male, mean age =58.87±12.37). Using ROC curve analysis, the calculated risk score is considered statistically significant for diagnostic accuracy (AUC = 0.862 [0.797–0.927], P value<0.001). A risk score cutoff greater than 1.5 (sensitivity 89.9%, specificity 38.9%) favors an increased likelihood of in-hospital mortality. According to multiple linear regression (F (9,93) =3.369, P value=0.001), chronic obstructive pulmonary disease, asthma, diabetes, SOFA score on day 2 & 3, and ventilation support were predictors of ICU length of stay.
Conclusion: A history of chronic heart failure with renal impairment, liver cirrhosis with liver complication, and any underlying disease are associated with pulmonary complications in COVID-19 patients.

[1] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song, ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265–9.
[2] Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24(6): 490–502.
[3] Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020; 92(4): 441–7.
[4] Iravani B, Arshamian A, Lundström JN. Loss of olfactory sensitivity is an early and reliable marker for COVID-19. Chem Senses. 2022; 47: bjac022.
[5] Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in humans: a descriptive study. Chin Med J (Engl). 2020; 133(9): 1015–24.
[6] Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020; 158(6): 1518–9.
[7] Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5): e212–e3.
[8] Zhou Y, Duan C, Zeng Y, Tong Y, Nie Y, Yang Y, et al. Ocular findings and proportion with conjunctival SARS-CoV-2 in COVID-19 patients. Ophthalmology. 2020; 127(7): 982–3.
[9] Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020; 20(7): 773.
[10] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4): e21.
[11] Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020; 70(9): 311–22.
[12] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683–90.
[13] Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Prog Cardiovasc Dis. 2020; 63(5): 682–9.
[14] Wong SH, Lui RN, Sung JJ. COVID-19 and the digestive system. J Gastroenterol Hepatol. 2020; 35(5): 744–8.
[15] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5): 428–30.
[16] Samidoust P, Samidoust A, Samadani AA, Khoshdoz S. Risk of hepatic failure in COVID-19 patients: A systematic review and meta-analysis. Le Infezioni in Medicina. 2020; 28(suppl 1): 96–103.
[17] Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021; 11(3): e048391.
[18] Wu T, Zuo Z, Kang S, Jiang L, Luo X, Xia Z, et al. Multi-organ dysfunction in patients with COVID-19: A systematic review and meta-analysis. Aging Dis. 2020; 11(4): 874–94.
Files
IssueArticle in Press QRcode
SectionResearch Article(s)
Keywords
Critical Care Organ complication Heart Failure Respiratory complication Renal complication Covid 19 Survival

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Taheri P, Beig Mohammadi MT, Mohammadi M, Najafi A, Fattah Ghazi S, Varpaei HA. Prevalence and Risk Factors Associated with Organ Complications in Patients with COVID 19 Admitted to the Intensive Care Unit: A Cohort Study. Arch Anesth & Crit Care. 2025;.